Search
Mannitol busulfan
go.drugbank.com/drugs/DB12097ApprovedWithdrawnMm has been used in trials studying the treatment of Cocaine Dependence and Diabetes Mellitus, Type 2.
Evobrutinib
go.drugbank.com/drugs/DB15170InvestigationalEvobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability).
Dynorphin
go.drugbank.com/drugs/DB16146InvestigationalDynorphin is under investigation in clinical trial NCT00000244 (Effects of Dynorphin 1-13 on Heroin Addiction - 1).
C-peptide
go.drugbank.com/drugs/DB16187InvestigationalC-peptide is under investigation in clinical trial NCT00278980 (Effect of C-peptide on Diabetic Peripheral Neuropathy).
Zifibancimig
go.drugbank.com/drugs/DB19332InvestigationalZifibancimig is under investigation in clinical trial NCT04567303, focusing on participants with neovascular age-related macular degeneration.
Lexanersen
go.drugbank.com/drugs/DB17933InvestigationalLexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.
Idronoxil
go.drugbank.com/drugs/DB04915InvestigationalIdronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.
Synonyms: Haginin EBenzoylecgonine
go.drugbank.com/drugs/DB01515ExperimentalIllicitIt is formed by hydrolysis of cocaine in the liver, catalysed by carboxylesterases. It is excreted in the urine of cocaine users after processing in the liver. … It is the main pharmaceutical ingredient in the investigational drug Esterom, a topical solution used for the relief of muscle pain that is not FDA approved or on the market in the United States.
Betaxolol
go.drugbank.com/drugs/DB00195ApprovedInvestigationalA cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
NTx-265
go.drugbank.com/drugs/DB05649InvestigationalIn May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause